Structures by: Filip X.
Total: 12
C26H23Cl2N4O4,C7H7NO2
C26H23Cl2N4O4,C7H7NO2
Molecular pharmaceutics (2020)
a=9.7532(4)Å b=13.0997(6)Å c=14.7094(7)Å
α=65.035(5)° β=72.196(4)° γ=84.857(4)°
C26H23Cl2N4O4,C7H7NO2
C26H23Cl2N4O4,C7H7NO2
Molecular pharmaceutics (2020)
a=9.6678(5)Å b=12.9865(6)Å c=14.6942(7)Å
α=64.386(5)° β=71.962(4)° γ=85.754(4)°
?
C11H13N3O2S2
Acta Crystallographica Section B (2010) 66, 6 615-621
a=8.5364(2)Å b=15.0148(3)Å c=21.3846(3)Å
α=90.0° β=90.0° γ=90.0°
Cl,C17H21N2S
Cl,C17H21N2S
Crystal Growth & Design (2012) 12, 12 5846
a=14.9293(6)Å b=8.3361(2)Å c=15.5173(6)Å
α=90.00° β=118.565(5)° γ=90.00°
Cl,C17H20.36N2S
Cl,C17H20.36N2S
Crystal Growth & Design (2012) 12, 12 5846
a=14.8724(8)Å b=8.2589(3)Å c=15.3578(8)Å
α=90.00° β=118.665(7)° γ=90.00°
Cl,C17H21N2S
Cl,C17H21N2S
Crystal Growth & Design (2012) 12, 12 5846
a=14.9859(9)Å b=8.3369(3)Å c=15.5132(10)Å
α=90.00° β=118.882(8)° γ=90.00°
Cl,C17H21N2S
Cl,C17H21N2S
Crystal Growth & Design (2012) 12, 12 5846
a=14.8149(13)Å b=8.3237(5)Å c=15.5201(12)Å
α=90.00° β=117.588(11)° γ=90.00°
C26H29Cl2N4O4,C2HO4
C26H29Cl2N4O4,C2HO4
Crystal Growth & Design (2013) 13, 10 4295
a=10.51506(16)Å b=13.3330(2)Å c=20.3036(3)Å
α=90.00° β=96.6413(14)° γ=90.00°
C26H28Cl2N4O4,C4H4O4
C26H28Cl2N4O4,C4H4O4
Crystal Growth & Design (2013) 13, 10 4295
a=10.5094(6)Å b=11.7425(6)Å c=13.4568(5)Å
α=96.238(4)° β=98.973(4)° γ=105.330(5)°
C26H28Cl2N4O4,C4H5O4
C26H28Cl2N4O4,C4H5O4
Crystal Growth & Design (2013) 13, 10 4295
a=10.5261(8)Å b=11.7297(9)Å c=13.4580(11)Å
α=95.287(6)° β=99.302(7)° γ=104.429(7)°
C26H28Cl2N4O4,C6H10O4
C26H28Cl2N4O4,C6H10O4
Crystal Growth & Design (2013) 13, 10 4295
a=5.8721(3)Å b=8.3797(4)Å c=34.4919(14)Å
α=92.623(4)° β=93.859(4)° γ=103.791(4)°
Cl,C17H21N2S
Cl,C17H21N2S
Crystal Growth & Design (2012) 12, 12 5846
a=14.8123(8)Å b=8.3170(2)Å c=15.5334(8)Å
α=90.00° β=117.696(7)° γ=90.00°